An observational study in Anxiety, Stress and COVID - 19, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Completed at 1 site in France. Open to participants aged 18 Years to 29 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.
Among the 782 studies in COVID-19 with a site in France, this one is the 88th largest by enrollment of the 486 observational ones that give a count, is one of 59 that started in 2022, is one of 486 observational ones, and was the 781st registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Hospices Civils de Lyon · Sites in France
Ages 8–18
Laboratoire de la Mer · Sites in France
Ages 15 days+
Centre Hospitalier Régional d'Orléans · Sites in France
Ages 18+
Pfizer · Sites in France, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 29 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
782 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 57 · Phase 3 64 · Phase 4 4
First in 2016; this study’s year is marked. 59 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,322 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Median enrollment 130 across the 294 interventional studies, 298 across the 486 observational. Of the 530 that completed or were terminated, 39 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 782 have an industry lead sponsor. The 10 most frequent:
GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 208 studies on the registry; 100 are open to participants now.
GCS Ramsay Santé pour l'Enseignement et la Recherche has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05587894ANRS, Emerging Infectious DiseasesOPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial | 2026-12-31 |
| NCT07882186Assistance Publique - Hôpitaux de ParisAssessment of the Acceptability of, and Factors Associated With, Recommended Vaccinations During Pregnancy in Maternity Units in the Ile-de-France Region | 2027-03 |
| NCT03963622Unity Health TorontoCareful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19) | 2027-06 |
Add all 8 to your calendar (.ics) → With an account.
Among the 782 studies in COVID-19 with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Since the onset of COVID-19, studies conducted on the general population have shown an increase in the use of antidepressants and anxiolytics, a rise in domestic violence, and heightened demand for peri-urban housing offering more space and a better living environment.
Queues of students at food distribution points, along with the precarious situations and isolation faced by students with no alternative to cramped living quarters, have exposed the vulnerability of this population to the general public.
There is a lack of data regarding young people-and students in particular-a group known to be at higher risk than others of exhibiting symptoms of stress, anxiety, or depression.
Depression among students and young adults can impact their social lives, relationships, and quality of life. Indeed, studies have demonstrated a strong correlation between major depressive disorder and poor academic performance, unstable interpersonal relationships, suicidal thoughts and attempts, and difficulties with work.
Existing literature indicates a link between stress and the onset or persistence of anxiety and depression. As these conditions are too often conflated, it is important to distinguish stress from anxiety and depression.
Consequently, a study designed to assess levels of stress, anxiety, and depression-as well as the processes involved in their development and persistence among young people-would facilitate the implementation of appropriate and effective care.
Such a study is all the more necessary in the current context of the COVID-19 pandemic.
Identifying these disorders within specific populations and subgroups would enable the implementation of tailored care strategies, thereby helping to safeguard mental health.
The aim of this study is to assess current levels of stress, anxiety, and depression among young adults and students, and to investigate the underlying determinants.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
This study's enrollment of 1,322 is above the median of 268 across 3,209 observational studies indexed under COVID-19.
Browse COVID-19 studies →GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 208 studies on the registry; 100 are open to participants now.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adult patient between 18 and 29 years old
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Questionnaire
* Generalised anxiety disorder questionnaire * Questionnaire Patient Health Questionnaire-9 (PHQ-9) * Perceived Stress Scale questionnaire * Difficulties in Emotion Regulation Scale (DERS-16) questionnaire * Acceptance and action questionnaire * Perseverative Thinking Questionnaire * D-stress questionnaire * Electrostatic discharge questionnaire
Perceived Stress Scale (PSS) score :
The PSS-10 takes about 3 minutes to complete and produces a 0-40 score : * 0-13 low * 14-26 moderate * 27-40 high
Time frame: 3 months
Ran from May 2022 to primary completion in Sep 2022, 4 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GCS Ramsay Santé pour l'Enseignement et la Recherche →